Called the Verisante Aura, the device employs Raman spectroscopy to identify the molecular makeup of moles by changing the vibrational state of the molecular bonds in a skin growth. Shining a particular laser light on those bonds causes a shift in the kind of light that is reflected back to a sensor, and that shift belies exactly what kinds of molecules are there and in what concentration they exist.
The device then checks the spectral signature against a database containing examples of melanoma and other skin diseases. By simply shining some laser light on the skin, a doctor can get a near-instantaneous red or green light regarding whether a growth requires further diagnosis via biopsy. It’s not a magic wand for diagnosis, and regulatory agencies could take issue with the fact that clinicians might rely too heavily on such a technology, which could produce false negatives or otherwise discourage doctors from requesting a biopsy when one might be advisable. But it could also greatly inform the process by which dermatologists identify potential problem areas and reduce the number of needless biopsies which—aside form causing a certain degree of physical pain—tie up laboratories and pile onto overall health care costs.